Efficacy of IOP reduction and safety of Tapcom combination ophthalmic solution switched from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution.

Efficacy of IOP reduction and safety of Tapcom combination ophthalmic solution switched from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution. - Efficacy of IOP reduction and safety of Tapcom combination ophthalmic solution switched from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016052

Enrollment

Registered

2014-12-29

Start date

2014-12-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open angle glaucoma or ocular hypertension

Interventions

Switching from Tapros 0.0015% and Timoptol XE 0.5% ophthalmic solution to Tapcom combination ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: primary open angle glaucoma or ocular hypertension good adherence before the study initiation

Exclusion criteria

Exclusion criteria: some corneal abnormality or other diseases which may interfere with accurate IOP measurement history of glaucoma surgery contraindicated to Beta blockers

Design outcomes

Primary

Measure	Time frame
IOP reduction Adverse event	—

Countries

Japan

Contacts

Public ContactKenji Inoue

Inouye Eye Hospital Medical office

study@inouye-eye.or.jp03-3295-0911

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026